Cargando…

Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients

The aim of this study was to evaluate factors that impact on voriconazole (VRC) population pharmacokinetic (PPK) parameters and explore the optimal dosing regimen for different CYP2C19 genotypes in Chinese paediatric patients. PPK analysis was used to identify the factors contributing to the variabi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Lin, Huang, Shiqiong, Huang, Qi, Huang, Juanjuan, Feng, Zeying, He, Gefei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495004/ https://www.ncbi.nlm.nih.gov/pubmed/37695751 http://dx.doi.org/10.1371/journal.pone.0288794

Ejemplares similares

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients
por: Li, Zi-Wei, et al.
Publicado: (2017)

Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization
por: Li, SiChan, et al.
Publicado: (2022)

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children
por: Chen, Xiaomin, et al.
Publicado: (2022)

Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis
por: Jiang, Zhiwen, et al.
Publicado: (2022)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
por: Zhong, Xuefeng, et al.
Publicado: (2018)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
por: Chung, Hyewon, et al.
Publicado: (2015)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

2566. Effect of CYP2C19 on Voriconazole Pharmacokinetics in Children with Malignancy or Inborn Errors in Immunity
por: Shoji, Kensuke, et al.
Publicado: (2023)

A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis
por: Kim, Yun, et al.
Publicado: (2019)

Attitude and Needs Toward MTM Applications of Chronic Disease in China: A Questionnaire Survey
por: Huang, Shiqiong, et al.
Publicado: (2022)

Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases
por: Khan-asa, Buddharat, et al.
Publicado: (2020)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

1566. Population Pharmacokinetics of Voriconazole: Serum Albumin Status as a Novel Marker of Clearance and Dosage Optimization
por: Chantharit, Prawat, et al.
Publicado: (2019)

Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections
por: Chuwongwattana, Sumonrat, et al.
Publicado: (2020)

Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT
por: Sienkiewicz, Beata, et al.
Publicado: (2017)

Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections
por: Miao, Qiang, et al.
Publicado: (2019)

Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children
por: Chen, Juan, et al.
Publicado: (2022)

Risk Factors Affecting Clinical Outcome in Patients with Carbapenem-Resistant K. pneumoniae: A Retrospective Study
por: He, Gefei, et al.
Publicado: (2020)

Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients
por: Ebrahimpour, Sholeh, et al.
Publicado: (2017)

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats
por: Lee, Ji-Sang, et al.
Publicado: (2021)

Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study
por: Suetsugu, Kimitaka, et al.
Publicado: (2021)

Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report
por: Beata, Sienkiewicz, et al.
Publicado: (2017)

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults
por: Muhareb, Amin, et al.
Publicado: (2023)

Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children
por: Espinoza, N., et al.
Publicado: (2019)

Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children
por: Zhao, Yi-Chang, et al.
Publicado: (2021)

Population Pharmacokinetics and Initial Dosage Optimization of Tacrolimus in Pediatric Hematopoietic Stem Cell Transplant Patients
por: Liu, Xiao-Lin, et al.
Publicado: (2022)

Effects of voriconazole on population pharmacokinetics and optimization of the initial dose of tacrolimus in children with chronic granulomatous disease undergoing hematopoietic stem cell transplantation
por: Chen, Xiao, et al.
Publicado: (2021)

Predicting the Outcome of Voriconazole Individualized Medication Using Integrated Pharmacokinetic/Pharmacodynamic Model
por: Yang, Ping, et al.
Publicado: (2021)

Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age
por: Liu, Shujing, et al.
Publicado: (2022)

Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation
por: García-García, Irene, et al.
Publicado: (2021)

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib
por: Nyga, Rémy, et al.
Publicado: (2019)

Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
por: Schulz, Josefine, et al.
Publicado: (2022)

Impact of polymorphisms of pharmacokinetics‐related genes and the inflammatory response on the metabolism of voriconazole
por: Aiuchi, Naoya, et al.
Publicado: (2022)

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
por: Imamura, Chiyo K., et al.
Publicado: (2015)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique
por: Wang, Hui-jun, et al.
Publicado: (2021)

Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization
por: Zhang, Yahui, et al.
Publicado: (2021)

Application of different pharmacokinetic models to describe and predict pharmacokinetics of voriconazole in magellanic penguins following oral administration
por: Parsley, Ruth A., et al.
Publicado: (2018)

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
por: Mafuru, Magesa, et al.
Publicado: (2021)

Update on the optimal use of voriconazole for invasive fungal infections
por: Lat, Asma, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_s22n8jdortru5sktbjqjl13tsg